Colorectal Cancer Evaluation Measures

Once a company has conducted assessment and planning for colorectal cancer screening programs, and developed the specific tasks of implementation for these programs, it is time to develop the evaluation plan. This evaluation plan should be in place before any program implementation has begun.  

Metrics for worker productivity, health care costs, heath outcomes, and organizational change allow measurement of the beginning (baseline), middle (process), and results (outcome) of workplace health programs. It is not necessary to use all these metrics for evaluating programs. Some information may be difficult or costly to collect, or may not fit the operational structure of a company. These lists are only suggested approaches that may be useful in designing an evaluation plan.

These measures are designed for employee group assessment. They are not intended for examining an individual’s progress over time, which would raise concerns of employee confidentiality. For employer purposes, individual-level measures should be collected anonymously and only reported (typically by a third party administrator) in the aggregate, because the company’s major concerns are overall changes in productivity, health care costs, and employee satisfaction.

In general, data from the previous 12 months will provide sufficient baseline information and can be used in establishing the program goals and objectives in the planning phase, and in assessing progress toward goals in the evaluation phase. Ongoing measurements every 6 to 12 months after programs begin are usually appropriate measurement intervals, but measurement timing should be adapted to the expectations of the specific program.  

Colorectal cancer screening is a valuable early detection tool that can identify colorectal cancer at an early stage when treatment is more effective and less expensive.

  • The estimated annual national expenditure for colorectal cancer treatment is $5.5-$6.5 billion; inpatient hospital care accounts for 80% of this cost1
  • Because colorectal cancer is a disease of middle and old age, the costs related to colorectal cancer treatment are likely to increase as the population ages1
  • In 2007, 142,672 people were diagnosed with colorectal cancer, and 53,219 people died from it2

1.  Seifeldin R, Hantsch JJ. The economic burden associated with colon cancer in the United States. Clinical Therapeutics. 1999; 21(8): 1370-1379.

2.  U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2007 Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2010. Available at: